In our “Why I’m Running” series, Boston Marathon athletes share what’s inspiring them to make the 26.2-mile trek from Hopkinton to Boston. Looking for more race day content? Sign up for ...

Erratum: Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease We appreciate the shared commitment ...

Almost half of adults and children with neurofibromatosis type 1 (NF1) responded to the investigational MEK inhibitor mirdametinib, a large multicenter study of the rare condition showed. Overall, 53 ...